Xcell Therapeutics Inc. (373110) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Xcell Therapeutics Inc. (373110:KRX), powered by AI.

Current Price
₩1,407
P/E Ratio
-2.2
Market Cap
24.3B
Sector
Healthcare
What is the Xcell Therapeutics Inc. stock price forecast?

Xcell Therapeutics Inc. is currently trading at ₩1,407. View real-time AI analysis on Alpha Lenz.

What is Xcell Therapeutics Inc. insider trading activity?

View the latest insider trading data for Xcell Therapeutics Inc. on Alpha Lenz.

What is Xcell Therapeutics Inc.'s P/E ratio?

Xcell Therapeutics Inc.'s P/E ratio is -2.2.

Xcell Therapeutics Inc.

KRX · 373110
₩1,407-43(-2.97%)Market closedKRX regular session 09:00–15:30 KST
Ask about Xcell Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Xcell Therapeutics Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -134.4%. 3Y revenue CAGR of 24.1% highlights clear growth momentum.

Ask for details

Company Overview

Xcell Therapeutics Inc. is a biotechnology company focused on the research and development of advanced therapeutic solutions. Operating at the cutting edge of biotechnology, the company’s primary aim is to develop innovative treatments that address unmet medical needs. Xcell Therapeutics Inc. specializes in regenerative medicine, leveraging stem cell technology to create therapies that have significant implications for treating a variety of chronic and degenerative diseases. This company plays a crucial role in the healthcare sector by offering potential solutions that could transform current treatment paradigms for conditions such as heart disease, neurological disorders, and other critical illnesses. By emphasizing precision medicine, Xcell Therapeutics Inc. impacts both medical research and clinical applications, contributing to more personalized and effective healthcare solutions. The company's efforts are significant in advancing the frontier of medical science, highlighting the growing importance of biotechnology firms in driving future healthcare innovations.

CEO이의일
SectorHealthcare
IndustryBiotechnology
Employees67

Company Statistics

FY 2025

Profile

₩24,333,212,358Market Cap
₩1,948,989,100Revenue
17.29MShares Out
67Employees

Margins

-100.29%Gross
-479.08%EBITDA
-556.79%Operating
-560.65%Pre-Tax
-560.65%Net

Valuation

-2.23P/E
3.41P/B
12.48EV/Sales
-2.97EV/EBITDA
-2.28P/FCF

Growth (CAGR)

24.09%Rev 3Yr
29.26%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-67.01%ROA
-134.41%ROE
-66.99%ROIC

Financial Health

₩2,093,846,110Cash & Cash Equivalents
₩6,489,476,930Net Debt
120.25%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Xcell Therapeutics Inc. (ticker: 373110) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 67 employees. Market cap is $24.3B.

The current price is ₩1,407 with a P/E ratio of -2.23x and P/B of 3.41x.

ROE is -134.41% and operating margin is -556.79%. Annual revenue is $1.9B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Xcell Therapeutics Inc. (373110) Stock Forecast 2026 ₩1,407 — Price, Financials & Analyst Targets | Alpha Lenz